nach oben

Erschienen in:

01.12.2021 | Evidence-Based Medicine, Clinical Trials and Their Interpretations (K. Nasir, Section Editor)

Differences in the 2020 ESC Versus 2015 ESC and 2014 ACC/AHA Guidelines on the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation

verfasst von: Mohammad Keykhaei, Haleh Ashraf, Sina Rashedi, Hossein Farrokhpour, Behnam Heidari, Shaghayegh Zokaei, Sayna Bagheri, Roham Foroumadi, Sara Asgarian, Aslan Amirian, Shahrokh Karbalai Saleh, Stefan James

Erschienen in: Current Atherosclerosis Reports | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

We assessed the differences in the 2020 European Society of Cardiology (ESC) versus 2015 ESC and 2014 American College of Cardiology (ACC) guidelines on the management of non-ST-segment elevation acute coronary syndromes (NSTE-ACS).

Recent Findings

The recent publication of the 2020 ESC has provided a comprehensive series of recommendations on diagnosis and management of patients presenting with NSTE-ACS. However, there are discrepancies between the 2020 ESC versus 2015 ESC and 2014 ACC guidelines, creating uncertainty among clinicians in routine practices. Our investigation provides insights into several domains, including diagnosis, risk stratification, pharmacological treatments, invasive treatment, and special populations.

Summary

Overall, it seems that the 2020 version of the ESC guideline for the management of NSTE-ACS provides the most evidence-based recommendations for clinicians; although due to the lack of validated investigation across some of the proposed recommendations, further longitudinal multicenter studies are warranted to address the current questions.

Graphical abstract

Diagnostic algorithm in NSTE-ACS. Abbreviations: ACC = American College of Cardiology; CABG = coronary artery bypass grafting; CCTA = coronary computed tomography angiography; CMR = cardiac magnetic resonance; CS = cardiogenic shock; ECG = electrocardiography; eGFR = estimated glomerular filtration rate; ESC = European Society of Cardiology; GRACE = Global Registry of Acute Coronary Events; HF = heart failure; LVEF = left ventricular ejection fraction; MPI = myocardial perfusion imaging; MR = mitral regurgitation; NSTE-ACS = non-ST-segment elevation acute coronary syndromes; PCI = percutaneous coronary intervention; TIMI = thrombolysis in myocardial infarction

Nur mit Berechtigung zugänglich

Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England). 2018;392(10159):1736–88. doi:https://doi.org/10.1016/s0140-6736(18)32203-7.

GBD Compare. Institute for Health Metrics and Evaluation. https://vizhub.healthdata.org/gbd-compare/. Accessed February 6 2021.

Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010.CrossRefPubMedPubMedCentral

Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77. https://doi.org/10.1093/eurheartj/ehz425.CrossRefPubMed

•• Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European heart journal. 2020. https://doi.org/10.1093/eurheartj/ehaa575. The 2020 ESC guideline for the management of NSTE-ACS provides the most evidence-based recommendations for clinicians on how to accurately diagnose and manage these groups of patients.

•• Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European heart journal. 2016;37(3):267-315. https://doi.org/10.1093/eurheartj/ehv320. Comparing the results of this study (2015 ESC) with the 2020 ESC guideline for the management of patients with NSTE-ACS could provide critical insights about the latest updates in the management of NSTE-ACS.

•• Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Jr., Ganiats TG, Holmes DR, Jr. et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2014;64(24):e139-e228. https://doi.org/10.1016/j.jacc.2014.09.017. Comparing the findings of this study (2014 ACC) with the 2020 ESC guideline for the management of patients with NSTE-ACS could pave the way for better understanding the latest insights for these group of patients.

Smulders MW, Kietselaer B, Wildberger JE, Dagnelie PC, Brunner-La Rocca HP, Mingels AMA, et al. Initial imaging-guided strategy versus routine care in patients with non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2019;74(20):2466–77. https://doi.org/10.1016/j.jacc.2019.09.027.CrossRefPubMed

Linde JJ, Kelbæk H, Hansen TF, Sigvardsen PE, Torp-Pedersen C, Bech J, et al. Coronary CT angiography in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2020;75(5):453–63. https://doi.org/10.1016/j.jacc.2019.12.012.CrossRefPubMed

10.

Chew DP, Astley CM, Luker H, Alprandi-Costa B, Hillis G, Chow CK, et al. A cluster randomized trial of objective risk assessment versus standard care for acute coronary syndromes: rationale and design of the Australian GRACE Risk score Intervention Study (AGRIS). Am Heart J. 2015;170(5):995-1004.e1. https://doi.org/10.1016/j.ahj.2015.07.032.CrossRefPubMed

11.

Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019;40(31):2632–53. https://doi.org/10.1093/eurheartj/ehz372.CrossRefPubMedPubMedCentral

12.

Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315(16):1735–49. https://doi.org/10.1001/jama.2016.3775.CrossRefPubMedPubMedCentral

13.

• Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet (London, England). 2017;389(10073):1025-34. doi:https://doi.org/10.1016/s0140-6736(17)30397-5. This study revealed that the PRECISE-DAPT score could provide a robust tool for the prediction of out-of-hospital bleeding during DAPT in patients with NSTE-ACS.

14.

•Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. The New England journal of medicine. 2019;381(16):1524–34. https://doi.org/10.1056/NEJMoa1908973. Findings of this study indicated that the administration of prasugrel is preferred over ticagrelor in the pre-treatment of patients with NSTE-ACS.

15.

Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369(11):999–1010. https://doi.org/10.1056/NEJMoa1308075.CrossRefPubMed

16.

• Dworeck C, Redfors B, Angerås O, Haraldsson I, Odenstedt J, Ioanes D et al. Association of pretreatment with P2Y12 receptor antagonists preceding percutaneous coronary intervention in non-ST-segment elevation acute coronary syndromes with outcomes. JAMA network open. 2020;3(10):e2018735. https://doi.org/10.1001/jamanetworkopen.2020.18735. The ACCOAST study demonstrated no association between prasugrel pre-treatment and ischemic benefit, but inversely, with notably higher bleeding risk in patients with NSTE-ACS.

17.

Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–66. https://doi.org/10.1056/NEJMoa1409312.CrossRefPubMedPubMedCentral

18.

Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791–800. https://doi.org/10.1056/NEJMoa1500857.CrossRefPubMed

19.

• Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. The New England journal of medicine. 2017;377(14):1319-30. https://doi.org/10.1056/NEJMoa1709118. This study represented either rivaroxaban, ticagrelor, or prasugrel could be applied for post-interventional and maintenance treatment in NSTE-ACS patients at high risk of ischemic events and without increased HBR.

20.

Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381(12):1103–13. https://doi.org/10.1056/NEJMoa1904143.CrossRefPubMed

21.

Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA. 2015;313(13):1336–46. https://doi.org/10.1001/jama.2015.2323.CrossRefPubMed

22.

Nührenberg TG, Hochholzer W, Mashayekhi K, Ferenc M, Neumann FJ. Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: a meta-analysis of randomized-controlled trials. Clin Res Cardiol. 2018;107(9):807–15. https://doi.org/10.1007/s00392-018-1251-1.

23.

Bonello L, Laine M, Puymirat E, Lemesle G, Thuny F, Paganelli F, et al. Timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes and clinical outcomes: an updated meta-analysis. JACC Cardiovasc Interv. 2016;9(22):2267–76. https://doi.org/10.1016/j.jcin.2016.09.017.CrossRefPubMed

24.

Rathod KS, Koganti S, Jain AK, Astroulakis Z, Lim P, Rakhit R, et al. Complete versus culprit-only lesion intervention in patients with acute coronary syndromes. J Am Coll Cardiol. 2018;72(17):1989–99. https://doi.org/10.1016/j.jacc.2018.07.089.CrossRefPubMed

25.

Sardella G, Lucisano L, Garbo R, Pennacchi M, Cavallo E, Stio RE, et al. Single-staged compared with multi-staged PCI in multivessel NSTEMI patients: the SMILE trial. J Am Coll Cardiol. 2016;67(3):264–72. https://doi.org/10.1016/j.jacc.2015.10.082.CrossRefPubMed

26.

Layland J, Oldroyd KG, Curzen N, Sood A, Balachandran K, Das R, et al. Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. Eur Heart J. 2015;36(2):100–11. https://doi.org/10.1093/eurheartj/ehu338.CrossRefPubMed

Titel: Differences in the 2020 ESC Versus 2015 ESC and 2014 ACC/AHA Guidelines on the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation
verfasst von: Mohammad Keykhaei
Haleh Ashraf
Sina Rashedi
Hossein Farrokhpour
Behnam Heidari
Shaghayegh Zokaei
Sayna Bagheri
Roham Foroumadi
Sara Asgarian
Aslan Amirian
Shahrokh Karbalai Saleh
Stefan James
Publikationsdatum: 01.12.2021
Verlag: Springer US
Erschienen in: Current Atherosclerosis Reports / Ausgabe 12/2021
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-021-00976-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Graphical abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2021

Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress

Moving the Needle on Atherosclerotic Cardiovascular Disease and Heart Failure with Influenza Vaccination

Gene-Environment Interactions for Cardiovascular Disease

Statins and Inflammation

Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?